Sofinnova Partners

Synthace Raises $35M to Expand Access to Its Revolutionary R&D Technology for Life Changing Research

Retrieved on: 
Tuesday, November 16, 2021
Biotechnology, Health, Science, Other Science, Research, BioTek, Intelligence, Industry, Agtech, R, Cornerstone, Repligen, CEO, Farmer, Impossible Foods, COVID, McKinsey & Company, Growth, Automation, Investment, D, Facebook, Data analysis, Lead, Sofinnova, Future, Vaccine, Molecular biology, Meta, Solution, Therapy, Zoom, Drug discovery, Communication, GTM, Biology, Marketing, Horizons Ventures, Drug development, Management, Fine chemical, Biotechnology, Health, Science, Other Science, Research, Horizons Ventures, Sofinnova Partners, Synthace, HORIZONS VENTURES, SOFINNOVA PARTNERS, SYNTHACE

The investment will fuel commercial and go-to-market (GTM) growth as Synthace continues to radically reinvent the full value chain of life sciences R&D.

Key Points: 
  • The investment will fuel commercial and go-to-market (GTM) growth as Synthace continues to radically reinvent the full value chain of life sciences R&D.
  • But to maximize impact, we need to expand access and reach to customers across the globeat scale.
  • This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries.
  • To learn more about how Synthace is transforming life sciences for a better future visit www.synthace.com .

GlycoEra AG Raises CHF 45 Million (US$ 49 Million) Series A Financing to Develop Novel Biologics Based on Innovative Glycoengineering Platform

Retrieved on: 
Friday, November 5, 2021
Professional Services, Health, Finance, Research, Science, Pharmaceutical, Biotechnology, CEO, Doctor of Philosophy, Technology, Veteran, Growth, Investment, Sofinnova, Lead, Board, Therapy, Glycosylation, Pharmaceutical industry, Cryptocurrency, Fine chemical, GlycoEra AG, 5AM Ventures, Roche Venture Fund, Sofinnova Partners, GLYCOERA AG, 5AM VENTURES, ROCHE VENTURE FUND, SOFINNOVA PARTNERS

GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners.

Key Points: 
  • GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners.
  • LimmaTech Biologics AG, from which GlycoEra was spun-out, also participated in this round.
  • GlycoEras innovative CustomGlycan platform unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics for a broad range of indications.
  • The Roche Venture Fund invests in early stage biotech and diagnostics companies to develop commercially successful innovative life science companies.

Sofinnova Partners Congratulates Portfolio Company DNA Script for the Success of Its €142M ($165M) Oversubscribed Series C Fundraise

Retrieved on: 
Tuesday, October 26, 2021
Research, Finance, Genetics, Professional Services, Biotechnology, Health, Pharmaceutical, General Health, Science, SYNTAX, Enzyme, Research, Biotechnology, Technology, Sofinnova, Partner, EDS, View, Lead, Food, Investment, CEO, Board, Growth, Organic acid, Organic, Script, Board of directors, DNA, Fine chemical, Sofinnova Partners, DNA Script, SOFINNOVA PARTNERS, DNA SCRIPT

DNA Script is a pioneer in Enzymatic DNA Synthesis (EDS) and DNA printing on demand.

Key Points: 
  • DNA Script is a pioneer in Enzymatic DNA Synthesis (EDS) and DNA printing on demand.
  • DNA Script is a leader in enzymatic DNA synthesis and has developed a revolutionary platform that provides in-house DNA printing using a sustainable process that eliminates the use of toxic organic chemicals.
  • Thomas Ybert, co-founder and CEO of DNA Script, said: Sofinnova Partners was our first institutional investor and a strong believer in our vision from the beginning.
  • Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.

DGAP-News: iOmx Therapeutics raises EUR 65 million in Series B round

Retrieved on: 
Tuesday, October 5, 2021
Apollon, MSD, EUR, VC, Precision medicine, German Cancer Research Center, DGAP, Family, Growth, Wellington Partners, Investment, Artificial intelligence, Volkswagen, Gesellschaft mit beschränkter Haftung, CEO, Science, Boston Scientific, Lead, Machine learning, Supervisory board, Cancer, Neoplasm, Therapy, BioNTech, PD-1, Sofinnova, AZ, J&J, MIG, News, List of life sciences, MD, Ambu, PerkinElmer, Nasdaq, Security (finance), Fine chemical, Vaccine, iOmx Therapeutics, Athos Service GmbH, M Ventures, MIG Capital AG, Sofinnova Partners, Wellington Partners, IOMX THERAPEUTICS, ATHOS SERVICE GMBH, M VENTURES, MIG CAPITAL AG, SOFINNOVA PARTNERS, WELLINGTON PARTNERS

Financing round with top-tier life science venture capitalists, led by Athos Service and MIG Capital, joined by existing shareholders

Key Points: 
  • Financing round with top-tier life science venture capitalists, led by Athos Service and MIG Capital, joined by existing shareholders
    The new funds will be used to advance iOmx' lead programs IMT-07 and IMT-18, both addressing novel immune checkpoint targets in oncology
    Martinsried / Munich, Germany, 5 October, 2021 - iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the closing of a Series B round totaling EUR 65 million.
  • He added: "We are pleased to join a world-class investor consortium and to begin to work with a highly talented and dedicated team at iOmx".
  • Dr. Gerald Moeller, Chairman of iOmx' Supervisory Board commented: "We now have the financial power to dynamically move forward.
  • iOmx Therapeutics ( www.iomx.com ) is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune checkpoints hijacked by cancer cells.

TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage

Retrieved on: 
Tuesday, August 31, 2021
Science, Cardiology, Biotechnology, Research, Surgery, Health, Medical Devices, Other Health, Company, Growth, Laboratory, Sofinnova, MIT, Lead, Cathay, Investment, Hernia, Patient, Solution, CEO, Medtech, Partner (business rank), Technology, Professor, Construction, Airline, TISSIUM, Cathay Health and Cathay Capital Group, Sofinnova Partners, TISSIUM, CATHAY HEALTH AND CATHAY CAPITAL GROUP, SOFINNOVA PARTNERS

As part of the financing, Cathay Health Co-founder and Managing Partner Hongjie Hu will be joining TISSIUMs board of directors.

Key Points: 
  • As part of the financing, Cathay Health Co-founder and Managing Partner Hongjie Hu will be joining TISSIUMs board of directors.
  • Christophe Bancel, CEO of TISSIUM, said, With the closing of our Series C financing round, TISSIUM is well-positioned to take the next steps to commercialization.
  • Hongjie Hu, Co-founder and Managing Partner of Cathay Health, said, TISSIUM is creating the future of tissue reconstruction on all continents.
  • Affiliated to Cathay Capital, Cathay Health is a global cross-border platform investing at the convergence of healthcare, life sciences and technology.

Protera Announces Final Close of Its $10M Series A Led by Sofinnova Partners

Retrieved on: 
Wednesday, July 28, 2021
Technology, Supermarket, Other Science, Food, Beverage, Environment, Research, Retail, Fitness & Nutrition, Biotechnology, Health, Other Natural Resources, General Health, Agriculture, Science, Natural Resources, Other Manufacturing, Other Technology, Software, Chemicals, Plastics, Data management, Other Retail, Manufacturing, Other Health, Sofinnova, Protera, Sofinnova Partners, Grupo Bimbo, ICL, PROTERA, SOFINNOVA PARTNERS, GRUPO BIMBO, ICL

The round was led by Sofinnova Partners , a leading European life sciences venture capital firm specialized in healthcare and sustainability.

Key Points: 
  • The round was led by Sofinnova Partners , a leading European life sciences venture capital firm specialized in healthcare and sustainability.
  • These key strategic partners will help Protera close the loop between highly effective protein design, production and commercialization of new protein-based ingredients.
  • Protera is currently scaling-up its manufacturing process and validating its protein-based ingredients with several multinational companies.
  • Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.

Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m

Retrieved on: 
Thursday, January 28, 2021
Health, Stem cells, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Finance, Money, Corporate finance, Economy, Private equity, Equity securities, Venture capital, Entrepreneurship, Enthera, the Roche Venture Fund, Sofinnova Partners, AbbVie Ventures, the JDRF T1D Fund

The Series A marks both the Roche Venture Funds and AbbVies first venture investment into an Italian biotech company.

Key Points: 
  • The Series A marks both the Roche Venture Funds and AbbVies first venture investment into an Italian biotech company.
  • As part of the Series A round, Carole Nuechterlein, Head Roche Venture Fund, joins the Enthera Board of Directors.
  • The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Entheras lead candidate.
  • Commenting on the successful Series A financing, Giovanni Amabile, CEO of Enthera, said: Having the Roche Venture Fund close out our Series A fundraising boosts our international investor syndicate and provides further validation of the work being done at Enthera.

DGAP-News: Gradient Denervation Technologies Raises €3.5M in Seed Funding with Sofinnova Partners

Retrieved on: 
Thursday, September 17, 2020
Medicine, Clinical medicine, Hypertension, Sofinnova, Medical specialties, Medical terminology, Denervation, Minimally invasive procedure, Pulmonary hypertension, Interventional radiology, Renal sympathetic denervation, Gradient Denervation Technologies, Sofinnova Partners, Sofinnova MD Start III

PARIS, FRANCE / ACCESSWIRE / September 17, 2020 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a 3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology.

Key Points: 
  • PARIS, FRANCE / ACCESSWIRE / September 17, 2020 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a 3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology.
  • Founded in February 2020, Gradient Denervation Technologies ("Gradient") builds on an innovation from two clinicians from Stanford University, Dr. Swami Gnanashanmugam and Dr. Jeffrey Feinstein.
  • Gradient Denervation Technologies develops a device-based minimally invasive solution for the treatment of pulmonary hypertension with technology developed by two clinicians from Stanford University.
  • It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund and based in Paris, France.

Enthera Pharmaceuticals Raises €28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and Inflammatory Bowel Disease

Retrieved on: 
Tuesday, July 28, 2020
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Inflammatory bowel disease, IBD, Enthera, Sofinnova Partners, AbbVie Ventures, the JDRF T1D Fund

The 28 million raised is the largest VC-backed Series A funding round for an Italian biotechnology company to date.

Key Points: 
  • The 28 million raised is the largest VC-backed Series A funding round for an Italian biotechnology company to date.
  • The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Entheras lead candidate.
  • Enthera was formed in 2016 on the basis of research by scientific founders Prof. Paolo Fiorina and Dr. Francesca DAddio.
  • The Companys primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).

DGAP-News: MastOR Secures Seed Funding from Sofinnova Partners to Develop its Laparoscopy Assistance Platform

Retrieved on: 
Thursday, July 2, 2020
Medicine, Clinical medicine, Endoscopy, Surgery, Laparoscopy, Minimally invasive procedure, Sofinnova, Robot-assisted surgery, MastOR, Sofinnova Partners, Sofinnova MD Start III

The funding will be used to advance MastOR's laparoscopy assistance platform, which broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

Key Points: 
  • The funding will be used to advance MastOR's laparoscopy assistance platform, which broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.
  • MastOR leverages the power of surgical robotics and existing laparoscopy instruments to offer a ubiquitous, affordable and modular platform delivering pristine surgical assistance in minimally-invasive digestive procedures.
  • MastOR SAS is a Paris-based, early stage medical device company, developing a surgical robot for laparoscopy assistance.
  • Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies.